Evaluating the Role of CAR T-Cell Therapy in Relapsed/Refractory DLBCL

February 12, 2020

Karl M. Kilgore, PhD, discusses the role of chimeric antigen receptor T-cell therapy as treatment of patients with relapsed/refractory diffuse large B-cell lymphoma and where this option might fit into the landscape in the future.

Karl M. Kilgore, PhD, senior research scientist, Avalere Health, discusses the role of chimeric antigen receptor (CAR) T-cell therapy as treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and where this option might fit into the landscape in the future.

Based on real-world data of the approved CAR T-cell therapies in DLBCL, Kilgore says the data are fairly optimistic in this patient population. There are not many treatment options available, and recent data have demonstrated CAR T cells are effective in this population, even in the patients who are older and have multiple comorbidities.

Physicians could consider CAT T-cell therapy a viable option for patients with relapsed/refractory DLBCL and as a viable treatment alternative in select patients. In the future, this therapy may even move earlier on in the course of treatment, Kilgore says.

<< View more resources and information regarding DLBCL